生态学与毒理学杂志

抽象的

Patients' Reimbursement Trade-offs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments are Simulated by Mushroom Cementation of Bio - based products from Microbial degradation of Radioactive Cellulosic-Based Material

Jacky P

In the current study, solidification of bioproducts produced by the bioremediation of a combination of radioactive waste made of solid cellulose was investigated in Portland cement. After 28 and 90 days of cure, the resultant solidified waste form was evaluated for mechanical integrity. Over the course of 540 days, the chemical performance of the cement-waste form was also assessed in various leaching media. The collected provided useful information regarding the final cement-waste form that contained the radioactive bioproducts in terms of its mechanical, physical, and chemical capabilities. Additionally, it revealed that cement can operate as a first line of defence against the release of radioactive pollutants from radioactive wastes to the environment and can offer a highly durable form that ensures the long-term stability of the solidified waste material.

The purpose of this study was to evaluate patients' preferences for when to begin systemic therapy and how to help them decide whether to trade off certain severe adverse events (AEs) for additional progression-free survival months (PFS). Materials and Techniques A direct-elicitation question and a discrete-choice experiment (DCE) were completed online by adults in France, Germany, and Spain who have been diagnosed with DTC and have received at least one RAI therapy. Respondents were asked if they would choose not to get treatment if their tumour was RAI-R in a direct-elicitation question. Respondents had 12 pairs of fictitious RAI-R DTC treatment profiles to select from in the DCE. Dimensions of effectiveness (PFS) and safety served as the benchmarks for profiling (severe hand-foot skin reaction [HFSR], severe proteinuria, and severe hypertension). The estimated logit model used main-effects randomparameters.The survey had 134 patients respond. Eighty-six percent of patients chose therapy over a "wait and see" strategy. Compared to the risks of proteinuria and HFSR, patients gave more weight to the risk of severe hypertension.In contrast to watchful waiting, DTC patients preferred therapy for RAI-R DTC. Severe proteinuria or HFSR seems to have less of an impact on patients' decisions than their worries about the possibility of developing severe hypertension.